Appearance of thrombogenic tendency induced by adrenaline and its prevention by  -adrenergic blocking agent, nialamide and pyridinolcarbamate.
D000284:Administration, Oral; D001772:Blood Cell Count; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D001792:Blood Platelets; D001794:Blood Pressure / Q000187:drug effects; D002219:Carbamates / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004837:Epinephrine / Q000008:administration & dosage*; D004983:Ethanolamines / Q000008:administration & dosage; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006402:Hematologic Diseases / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases; D008297:Male; D000432:Methanol / Q000008:administration & dosage; D009526:Nialamide / Q000008:administration & dosage*; D009638:Norepinephrine / Q000008:administration & dosage; D010643:Phenoxybenzamine / Q000008:administration & dosage; D010919:Placebos; D010973:Platelet Adhesiveness; D011725:Pyridines / Q000008:administration & dosage; D013610:Tachycardia / Q000139:chemically induced
D002219:Carbamates; D004983:Ethanolamines; D005230:Fatty Acids, Nonesterified; D010919:Placebos; D011725:Pyridines; D010643:Phenoxybenzamine; D009526:Nialamide; D009638:Norepinephrine; D000432:Methanol; D004837:Epinephrine